Last updated: September 7, 2026
Zavegepant hydrochloride, marketed in the United States as Zavzpret, is Pfizer’s intranasal calcitonin gene-related peptide, or CGRP, receptor antagonist for the acute treatment of migraine with or without aura in adults. The FDA approved Zavzpret in March 2023. Its commercial value depends on differentiation from oral gepants, triptans and injectable CGRP products rather than on broad preventive-migraine use.
Pfizer has not publicly disclosed Zavzpret revenue as a standalone line item. The product is commercially important as part of Pfizer’s migraine portfolio, but its near-term sales ceiling is constrained by competing products, payer controls, a predominantly acute-treatment indication and Pfizer’s own oral migraine products.
What is zavegepant hydrochloride and how does Zavzpret work?
Zavegepant hydrochloride is a small-molecule CGRP receptor antagonist administered through a nasal spray. Each device delivers 10 mg of zavegepant. The FDA-approved indication is the acute treatment of migraine with or without aura in adults, not preventive migraine treatment. [1]
Its principal clinical differentiation is the nonoral route of administration. Zavzpret may be used when migraine-related nausea, vomiting or gastrointestinal dysfunction makes oral treatment less practical. The product is also positioned for patients who want a non-injectable alternative to subcutaneous or intravenous therapies.
FDA regulatory status
| Item |
Status |
| Active ingredient |
Zavegepant hydrochloride |
| Brand |
Zavzpret |
| Sponsor and commercial company |
Pfizer |
| Original developer |
Biohaven Pharmaceutical Holding Company |
| FDA approval |
March 9, 2023 |
| Dosage form |
10 mg nasal spray |
| Approved use |
Acute treatment of migraine with or without aura in adults |
| Preventive indication |
Not approved |
| Route |
Intranasal |
| Product type |
Small-molecule prescription drug |
Pfizer obtained zavegepant through its 2022 acquisition of Biohaven’s commercial and pipeline assets. The transaction included Nurtec ODT, zavegepant and other migraine-related programs. [2]
How large is the zavegepant and acute migraine market?
The addressable migraine market is large, but the commercially relevant segment for Zavzpret is narrower. The product competes within acute prescription treatment, where patients and prescribers already have access to generic triptans, oral gepants and established branded products.
The migraine market has several overlapping segments:
| Segment |
Representative products |
Commercial relevance to Zavzpret |
| Generic acute therapy |
Sumatriptan, rizatriptan, eletriptan |
Low price and broad payer access create a barrier |
| Oral gepants |
Ubrelvy, Nurtec ODT, Zavzpret’s portfolio competitors |
Direct mechanism and brand competition |
| Preventive oral gepants |
Qulipta, Nurtec ODT |
Compete for prescriber attention and payer budgets |
| Injectable CGRP therapies |
Aimovig, Ajovy, Emgality, Vyepti |
Mostly preventive, with different use patterns |
| Dihydroergotamine products |
Trudhesa and others |
Alternative nonoral acute treatment |
| Neuromodulation devices |
Prescription and consumer devices |
Nonpharmaceutical substitution |
Zavzpret’s market opportunity is strongest among patients who need acute therapy but cannot reliably use tablets. That includes patients with severe nausea, vomiting, rapid symptom escalation or inadequate response to oral agents.
Its market is weaker among patients who tolerate oral treatment and receive low-cost generic triptans. Payers generally require step therapy or prior authorization before covering higher-priced branded gepants.
What are the main commercial advantages of zavegepant?
The strongest commercial attributes are route of administration, rapid usability during migraine and absence of vasoconstriction associated with triptans. The product can be used by patients for whom triptans are ineffective, poorly tolerated or clinically unsuitable.
Intranasal delivery
The nasal route gives Pfizer a product distinction that oral gepants do not have. It also creates a separate prescribing rationale for patients who experience vomiting or difficulty swallowing during an attack.
The route is not an automatic guarantee of superior market access. Nasal administration can create adherence and acceptance issues, including device handling, nasal irritation, taste disturbance and reluctance to use a spray during an attack. Commercial adoption therefore depends on whether patients perceive the delivery advantage as meaningful.
CGRP mechanism
Zavegepant blocks the CGRP receptor without the vasoconstrictive mechanism associated with triptans. That expands its potential use among some patients with cardiovascular risk factors, subject to the prescribing information and physician judgment.
Acute-only positioning
Zavzpret’s approved use is acute treatment. It does not compete directly with preventive therapies for the same prescription, but Pfizer may use it to strengthen migraine account coverage alongside Nurtec ODT and Qulipta.
How does Zavzpret compare with Nurtec ODT, Ubrelvy and triptans?
| Product |
Ingredient |
Route |
Acute use |
Preventive use |
Key competitive issue |
| Zavzpret |
Zavegepant |
Nasal spray |
Yes |
No |
Nonoral CGRP option |
| Nurtec ODT |
Rimegepant |
Orally disintegrating tablet |
Yes |
Yes |
Broad indication and Pfizer portfolio overlap |
| Ubrelvy |
Ubrogepant |
Oral tablet |
Yes |
No |
Established oral gepant competitor |
| Sumatriptan generics |
Sumatriptan |
Oral, nasal, injectable |
Yes |
No |
Low cost and payer preference |
| Trudhesa |
Dihydroergotamine |
Nasal delivery |
Yes |
No |
Nonoral legacy mechanism |
| Qulipta |
Atogepant |
Oral tablet |
No |
Yes |
Preventive CGRP competition |
Nurtec ODT is the most important internal comparator. Both products address acute migraine, while Nurtec also has a preventive indication. Pfizer can use Nurtec for patients who prefer oral administration and Zavzpret for patients who need a nonoral option. The products also compete for the same neurology and primary-care prescribing relationships.
Ubrelvy has first-mover advantages in the oral gepant category and a strong prescriber base. Generic triptans remain the principal economic competitor because they are inexpensive and familiar to payers.
What is the financial trajectory for Zavzpret?
Zavzpret’s financial trajectory is difficult to measure from Pfizer’s public reporting because Pfizer does not separately report product-level sales for the drug. The company reports major products individually, but Zavzpret is generally grouped within broader commercial or emerging-product disclosures rather than presented as a standalone revenue line. [3]
Revenue outlook
The likely trajectory has four phases:
- Launch phase, 2023: Initial uptake was driven by neurologists, migraine specialists and patients seeking nonoral acute treatment.
- Access expansion, 2024-2025: Commercial performance depends on payer coverage, pharmacy availability, repeat prescribing and integration with Pfizer’s migraine sales force.
- Portfolio optimization: Pfizer can position Zavzpret alongside Nurtec ODT and Qulipta, using one commercial platform across acute and preventive migraine.
- Maturity and erosion: Later sales will depend on patent protection, competing gepants, generic substitution and potential settlement outcomes.
The product’s revenue potential is meaningful but unlikely to approach the scale of a broad chronic-use blockbuster without a preventive indication or substantial expansion into underserved acute-treatment populations.
Revenue drivers
Key positive drivers include:
- Increased diagnosis and treatment of migraine.
- Greater physician acceptance of gepants.
- Demand for nonoral acute treatment.
- Triptan intolerance or contraindications.
- Pfizer’s existing migraine commercial infrastructure.
- Cross-selling with Nurtec ODT and Qulipta.
- Growth in specialty pharmacy and telehealth prescribing.
Key negative drivers include:
- Generic triptan pricing.
- Prior authorization and step edits.
- Oral gepant competition.
- Limited dosing frequency and acute-only labeling.
- Patient reluctance to use nasal products.
- Lack of a preventive indication.
- Pfizer’s need to manage overlap between Zavzpret and Nurtec ODT.
What patents protect zavegepant hydrochloride?
Zavegepant is protected by a portfolio that may include composition-of-matter, pharmaceutical-composition, formulation, delivery-device, manufacturing and method-of-use rights. The commercially relevant analysis must distinguish patent claims covering the active molecule from claims covering the nasal formulation or specific clinical uses.
The FDA’s Orange Book is the controlling public source for patents and regulatory exclusivity associated with an approved small-molecule product. Orange Book listings can change through patent-listing updates, delistings, corrections or litigation outcomes. [4]
Patent categories relevant to Zavzpret
| Patent category |
Commercial function |
| Composition of matter |
Protects zavegepant or related chemical structures |
| Salt and crystalline-form claims |
May protect hydrochloride or solid-state properties |
| Pharmaceutical composition |
Covers drug-containing formulations |
| Nasal formulation |
Protects excipients, concentration or stability characteristics |
| Device and delivery claims |
May cover spray architecture or administration |
| Method of treatment |
Covers acute migraine treatment or patient subgroups |
| Manufacturing claims |
Can create process barriers for generic applicants |
The composition-of-matter patent is normally the most important barrier, but formulation and method-of-use patents can influence generic litigation and settlement economics. A generic applicant may challenge listed patents through an Abbreviated New Drug Application and a Paragraph IV certification.
When does Zavzpret lose exclusivity?
The exact loss-of-exclusivity date depends on the patents listed in the Orange Book, patent-term adjustment, pediatric exclusivity and any litigation settlement. FDA approval alone does not establish the commercial generic-entry date.
Zavzpret is a 2023-approved small molecule. Its regulatory exclusivity is distinct from patent exclusivity. New chemical entity exclusivity is generally five years from approval, although a Paragraph IV certification may be submitted after four years. [5]
Other potential protections include:
- Patent-term adjustment for qualifying prosecution delay.
- Pediatric exclusivity, if granted.
- Three-year exclusivity for a qualifying new clinical investigation.
- Formulation and method-of-use patents.
- Litigation settlements that establish an authorized or licensed generic-entry date.
A generic applicant can challenge patents before their nominal expiration. The practical launch date may therefore be determined by litigation, settlement or a court ruling rather than by the last listed patent expiration.
What Paragraph IV challenges and litigation affect zavegepant?
A Paragraph IV challenge would require a generic applicant to assert that an Orange Book-listed patent is invalid, unenforceable or not infringed. Filing an adequate patent-infringement action within 45 days can trigger a statutory stay of FDA approval for up to 30 months, subject to court action and statutory exceptions. [5]
No major publicly established Paragraph IV litigation outcome for zavegepant is included in Pfizer’s publicly reported commercial disclosures through the available reporting period. The risk profile will rise as the product approaches the end of its regulatory and patent-protected period.
The most consequential litigation questions will be:
- Whether generic applicants challenge the active ingredient or only formulation claims.
- Whether nasal-delivery claims survive validity review.
- Whether Pfizer lists sufficient patents to create a meaningful stay.
- Whether settlement agreements permit an authorized generic.
- Whether a generic product can obtain approval without infringing device claims.
What manufacturing and intellectual-property barriers affect generic entry?
Zavegepant generic entry may be more complex than entry for a conventional oral tablet. A generic nasal spray must demonstrate pharmaceutical equivalence and bioequivalence while matching critical device and formulation characteristics.
Potential barriers include:
- Manufacture of the active pharmaceutical ingredient.
- Control of particle size, impurities and salt form.
- Nasal-spray pump performance.
- Dose uniformity across the container.
- Stability and preservative systems.
- In-vitro performance testing.
- Container-closure compatibility.
- Device-related patent claims.
These barriers may delay entry even if a generic applicant succeeds on the active-ingredient patents. The strength of the barrier depends on whether the FDA accepts a conventional ANDA pathway or requires more extensive comparative evidence.
What is the competitive landscape for CGRP migraine drugs?
Pfizer operates in a crowded CGRP market. AbbVie sells Ubrelvy and Qulipta following its acquisition of Allergan, while Pfizer controls Nurtec ODT and Zavzpret. Teva, Eli Lilly and Lundbeck compete in preventive CGRP therapies.
The central competitive battle is shifting from mechanism to product experience. Most leading products target CGRP biology. Differentiation increasingly depends on route, dosing frequency, preventive versus acute labeling, tolerability, access and net price.
Zavzpret has a defensible position as a nasal acute-treatment gepant. Its weakness is that competitors can address the same patient need through oral, dissolving, injectable or other nasal products.
How strong is the zavegepant patent estate?
The patent estate is commercially useful but should not be treated as equivalent to a broad platform patent. A strong assessment requires claim-level review of Orange Book patents, prosecution history, expiration calculations and any continuation applications.
The estate is strongest if Pfizer has enforceable claims covering:
- The active zavegepant molecule.
- The hydrochloride salt or a commercially necessary solid form.
- The nasal formulation.
- The spray device or dose-delivery system.
- Acute migraine treatment methods.
The estate is weaker if generic applicants can design around formulation or device claims while relying on an unprotected or expired active-ingredient pathway.
What generic launch scenarios exist for Zavzpret?
| Scenario |
Timing pattern |
Commercial effect |
| No early challenge |
Entry after final patent expiry |
Longer branded revenue tail |
| Paragraph IV settlement |
Entry on negotiated date |
Predictable erosion, often gradual |
| Successful early challenge |
Launch before final listed expiry |
Rapid price and share pressure |
| Authorized generic |
Pfizer-linked generic launch |
Pfizer retains part of generic economics |
| Formulation workaround |
Generic avoids specific device claims |
Potentially earlier competition |
The most damaging scenario is an early generic launch supported by a successful invalidity or noninfringement ruling. Nasal-device complexity could reduce the number of early challengers, but it does not eliminate Paragraph IV risk.
What licensing deals and corporate transactions affect zavegepant?
Zavegepant entered Pfizer’s portfolio through the May 2022 acquisition of Biohaven’s commercial and pipeline assets. Pfizer paid approximately $11.6 billion for the transaction, while Biohaven’s existing shareholders retained rights to a separate company holding noncommercialized assets. [2]
The deal placed zavegepant inside a larger migraine franchise anchored by Nurtec ODT. This structure reduces standalone commercial costs because Pfizer can use existing specialty sales, payer and distribution infrastructure. It also creates internal portfolio competition, since Zavzpret and Nurtec ODT both address acute migraine.
What is the investment and revenue-exposure assessment?
Zavzpret is strategically relevant but unlikely to be a primary driver of Pfizer’s consolidated financial performance in the near term. Pfizer’s overall revenue is diversified across vaccines, oncology, inflammation, rare disease and other established medicines. The company does not provide enough public product-level information to isolate Zavzpret’s contribution to consolidated earnings.
For investors and licensing counterparties, the key variables are:
- Prescription growth and refill behavior.
- Net price after rebates.
- Commercial and Medicare coverage.
- Share captured from triptans and oral gepants.
- Incremental sales created for Pfizer’s migraine franchise.
- Patent litigation and settlement timing.
- Potential label expansion.
- Manufacturing reliability for the nasal device.
The product has a credible niche but faces a high competitive burden. Its financial trajectory is more likely to be a specialty growth asset than a single-product replacement for a major loss-of-exclusivity event.
Key Takeaways
- Zavegepant hydrochloride is the active ingredient in Pfizer’s Zavzpret nasal spray.
- The FDA approved Zavzpret on March 9, 2023, for acute migraine treatment in adults.
- Its principal differentiation is nonoral CGRP therapy for patients who cannot use or do not prefer oral treatment.
- Pfizer acquired zavegepant through its $11.6 billion Biohaven transaction.
- Pfizer does not publicly report Zavzpret revenue as a standalone financial line.
- Nurtec ODT is the closest internal comparator and gives Pfizer a broader migraine portfolio.
- Generic triptans and oral gepants are the main commercial threats.
- Patent and exclusivity timing depends on Orange Book listings, patent-term adjustments, pediatric exclusivity and litigation settlements.
- Nasal formulation and device requirements may raise generic-development complexity.
- Zavzpret has a defensible niche, but its acute-only label and crowded CGRP market limit its standalone blockbuster potential.
FAQs
Is zavegepant the same drug as Zavzpret?
Yes. Zavegepant hydrochloride is the active ingredient in Zavzpret, Pfizer’s 10 mg nasal spray for acute migraine treatment.
Can Zavzpret be used to prevent migraine?
No. The FDA-approved label covers acute treatment of migraine with or without aura in adults. It is not approved for migraine prevention.
Is Zavzpret a generic or a branded drug?
Zavzpret is a branded prescription drug marketed by Pfizer. It is a small-molecule product, so future competition would generally proceed through an ANDA and Paragraph IV framework rather than a biosimilar application.
Does Pfizer disclose Zavzpret sales separately?
No. Pfizer’s public financial reporting does not consistently provide Zavzpret revenue as a standalone line item. The product is reported within broader commercial categories or portfolio disclosures.
What is the main reason physicians prescribe Zavzpret instead of an oral gepant?
The principal reason is the nasal route. It may be useful for patients with migraine-related nausea, vomiting, swallowing difficulty or a preference for nonoral acute treatment.
References
- U.S. Food and Drug Administration. (2023). Zavzpret (zavegepant) nasal spray prescribing information. https://www.accessdata.fda.gov
- Pfizer Inc. (2022). Pfizer completes acquisition of Biohaven Pharmaceuticals’ commercial portfolio. https://www.pfizer.com/news/press-release
- Pfizer Inc. (2024). Annual report 2023, Form 10-K. https://www.pfizer.com/investors/financial-reports
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/development-resources/abbreviated-new-drug-application-anda
